uniQure (QURE) Income from Continuing Operations (2016 - 2026)
uniQure's (QURE) quarterly Income from Continuing Operations came in at 53535000.0 in Q1 2026, down 22.68% year-on-year from 69240546.4 in Q1 2025, and down 425.48% quarter-over-quarter from 16448000.0 in Q4 2025.
uniQure (QURE) Income from Continuing Operations (2016 - 2026) Analysis & Trends
uniQure's Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 53535000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 22.68% year-over-year to 53535000.0 in Q1 2026; TTM through Mar 2026 was 154230000.0, a 28.83% increase from a year earlier, with the FY2025 full-year figure at 143458000.0, up 39.54% from the prior year.
- Income from Continuing Operations fell to 53535000.0 in Q1 2026 per QURE's latest filing, from 16448000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 16448000.0 in Q4 2025 and bottomed at 89571000.0 in Q3 2023.
- The 5-year median for Income from Continuing Operations is 53535000.0 (2026), against an average of 51264823.53.
- Across the five-year window, Income from Continuing Operations tumbled 1443.78% in 2023 and soared 122.72% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 5313000.0 in 2022, then tumbled by 1443.78% to 71395000.0 in 2023, then fell by 1.39% to 72390000.0 in 2024, then jumped by 122.72% to 16448000.0 in 2025, then tumbled by 425.48% to 53535000.0 in 2026.
- Per Business Quant, the three latest QURE Income from Continuing Operations figures stand at 53535000.0 (Q1 2026), 16448000.0 (Q4 2025), and 79424000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | uniQure | 2.47 Bn | 2.47 Bn | 3.34 Mn | -53.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.54 Mn |
| Dec 31, 2025 | 16.45 Mn |
| Sep 30, 2025 | -79.42 Mn |
| Jun 30, 2025 | -37.72 Mn |
| Mar 31, 2025 | -43.64 Mn |
| Dec 31, 2024 | -72.39 Mn |
| Sep 30, 2024 | -44.38 Mn |
| Jun 30, 2024 | -56.30 Mn |
| Mar 31, 2024 | -65.62 Mn |
| Dec 31, 2023 | -71.40 Mn |
| Sep 30, 2023 | -89.57 Mn |
| Jun 30, 2023 | -68.47 Mn |
| Mar 31, 2023 | -77.23 Mn |
| Dec 31, 2022 | 5.31 Mn |
| Sep 30, 2022 | -47.86 Mn |
| Jun 30, 2022 | -39.06 Mn |
| Mar 31, 2022 | -46.68 Mn |
| Dec 31, 2021 | 11.42 Mn |
| Sep 30, 2021 | -36.53 Mn |
| Jun 30, 2021 | 399.47 Mn |